Four things to know:
1. Mr. Poole has held several executive roles at Medtronic over a 13-year period.
2. Most recently, he served as vice president of finance for Medtronic Spine and Biologics, a global business unit with more than $2.5 billion in annual revenue.
3. Mr. Poole speaks fluent Japanese and has lived and worked in Japan, where DiscGenics has a significant commercial interest.
4. DiscGenics has secured more than $71 million in funding to date and is focusing on clinical trials of its allogeneic, injectable disc cell therapy for lumbar degenerative disc disease.
More articles on devices:
Losing its orthopedic provider to a competitor, New York system taps new partner
Orthopedic rankings, robotics & more: 6 key developments at Mayo Clinic during the pandemic
11 new orthopedic centers in August: The Steadman Clinic, Rothman Orthopaedics & more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
